Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Nov 18, 2021 8:53pm
119 Views
Post# 34143636

RE:RE:RE:New post on LinkedIn

RE:RE:RE:New post on LinkedIn

Beliveau is a jolly guy, he has an infectious enthusiasm.


jfm1330 wrote: I just listen to it. They said nothing specific and nothing about the ongoing phase I. The host of the show talked about a cure for cancer three times, and also refered to SORT1 as the ultimate weapon against cancer, but neither Levesque or Beliveau acknowledged that when he interviewed them very shortly. This was not serious, and the host was totally superficial and over the top. Too much is like not enough.

The only interesting bit was when Dr. Beliveau said that up to now they did not see anything that went wrong with the SORT1 approach and that experimentations always confirmed their basic research thesis from the begining. He also said that the idea was to attack cancer on its weak spots, and that sortilin was a weak spot. Dr. Beliveau was all smile and very enthusiastic in his demeanor, like in the KOL presentation, but he only answered general superficial questions.

As for Levesque he was more restrained, and he said that he was as optimistic as Dr. Beliveau, but the key for him was the reaction of American investors that were in awe with the science they have and the preclinical data. He said that we will see what the future holds, but if the results are there, the money will follow. He also said that if Thera gets to the commercialization stage in oncology they will have to see if the company has all that is needed to do it alone. Also, Beliveau was asked how long it will take to get to the market in oncology, he did not answer, he just said that they have the fast track status from FDA and that it will help.

So it lasted only 5 minutes. It was filmed in Dr. Beliveau's labs at UQAM. Very superficial and sensationalist on the part of the host. The only real good thing is that they are willing to go on TV talking about it right now. My guess is that they would not do it if the phase Ia was going wrong.                                                                                   

 

<< Previous
Bullboard Posts
Next >>